Skip to main content
SpringerLink
Log in

Release-Active Antibodies to S100 Protein Can Correct the Course of Experimental Allergic Encephalomyelitis

  • Published:
Neuroscience and Behavioral Physiology Aims and scope Submit manuscript

Objective. To study the efficacy of release-active forms of antibody to S100 protein in an animal model of multiple sclerosis. Materials and methods. The study was performed on 60 female rats aged 12 weeks. Experimental allergic encephalomyelitis was induced by administration of spinal cord homogenate at the base of the tail. Female rats then received intragastric solution of release-active antibodies to S100 protein (Tenoten) at a dose of 2.5 ml/kg/day or distilled water for 30 days. Positive controls received i.m. injections of glatiramer acetate at a dose of 4 mg/kg/day (Copaxone). Results and discussion. Administration of release-active forms of antibody to S100 increased the latent period of disease onset, decreased in peak disease intensity, and compensated for weight loss in the animals, as compared with controls. The effect of the agents was comparable with that of the Copaxone group.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. R. Aharoni, “New findings and old controversies in the research of multiple sclerosis and its model experimental autoimmune encephalomyelitis,” Expert Rev. Clin. Immunol., 9, No. 5, 423–440 (2013), doi: 10.1586/eci.13.21.

    Article  CAS  PubMed  Google Scholar 

  2. E. G. Gilerovich, E. A. Fedorova, I. N. Abdurasulova, et al., “Analysis of the morphological signs of inflammatory reactions in the spinal cord of Wistar rats in an experimental model,” Morfologiya, 138, No. 5, 16–20 (2010).

  3. S. Sinha, S. Subramanian, L. Miller, et al., “Cytokine switch and bystander suppression of autoimmune responses to multiple antigens in experimental autoimmune encephalomyelitis by a single recombinant T-cell receptor ligand,” Neuroscience, 29, No. 1, 3816–3823 (2009), doi: 10.1523/jneurosci.5812-08.2009.

  4. A. V. Pozdnyakov, I. N. Abdurasulova, and L. N. Prakhova, “Proton magnetic resonance spectroscopy in studies of the metabolic mechanisms of demyelinating process in experimental allergic encephalomyelitis,” Zh. Luch. Diagnost. Ter., 2, No. 1, 30–36 (2010).

    Google Scholar 

  5. R. Donato, “Intracellular and extracellular roles of S100 proteins,” Microsc. Res. Tech., 60, No. 6, 540–551 (2003), doi: 10.1002/jemt.10296.

    Article  CAS  PubMed  Google Scholar 

  6. D. B. Zimmer, E. H. Cornwall, A. Landar, and W. Song, “The S100 protein family: history, function and expression,” Brain Res. Bull., 37, 417–429 (1995); 10.1016/0361-9230(95)00040-2.

  7. D. F. de Souza, K. Wartchow, F. Hansen, et al., “Interleukin-6-induced S100B secretion is inhibited by haloperidol and risperidone,” Prog. Neuropsychopharmacol. Biol. Psychiatry, 43,13–22 (2013), doi: 10.1016/j.pnpbp.2012.12.001.

    Article  Google Scholar 

  8. C. Adami, G. Sorci, E. Blasi, et al., “S100B expression in and effects on microglia,” Glia, 33, No. 2, 131–142 (2001), doi: 10.1002/1098-1136 (200102)33:2<131::aid-glia1012>3.3.co;2-4.

  9. G. Esposito, D. DeFilippis, C. Cirillo, et al., “The astroglial-derived S100beta protein stimulates the expression of nitric oxide synthase in rodent macrophages through p38 MAP kinase activation,” Life Sci., 78, No. 23, 2707–2715 (2006), doi: 10.1016/j.lfs.2005.10.023.

  10. J. Hu and L. J. Can Elkik, “Glial-derived proteins activate cultured astrocytes and enhance beta amyloid-induced glial activation,” Brain Res., 842, No. 1, 46–54 (1999), doi: 10.1016/s0006-8993(99) 01804-1.

  11. U. Missler, K. P. Wandinger, M. Wiesmann, et al., “Acute exacerbation of multiple sclerosis increases plasma levels of S-100 protein,” Acta Neurol. Scand., 96, 142–144 (1997), doi: 10.1111/j.1600-0404. 1997.tb00256.x.

  12. K. Mitosek-Szewczyk, W. Gordon-Krajcer, D. Flis, and Z. Stelmasiak, “Some markers of neuronal damage in cerebrospinal fluid of multiple sclerosis patients in relapse,” Folia Neuropathol., 49, No. 3, 191–196 (2011).

    CAS  PubMed  Google Scholar 

  13. E. I. Gusev, I. A. Belyaeva, V. P. Chekhonin, and T. L. Demina, “Clinical-immunochemical characteristics of the remitting course of multiple sclerosis,” Vestn. Ros. Akad. Med. Nauk., No. 7, 40–45 (1999).

  14. K. Kojima, H. Wekerle, H. Lassmann, et al., “Induction of experimental autoimmune encephalomyelitis by CD4+ T cells specific for an astrocyte protein, S100 beta,” J. Neural Transm. Suppl., 9, 43–51 (1997), doi: 10.1007/978-3-7091-6844-8_5.

    Google Scholar 

  15. O. I. Epshtein, “The phenomenon of release-activity and the ‘spatial homeostasis hypothesis’,” Usp. Fiziol. Nauk., 44, No. 3, 54–76 (2013).

    Google Scholar 

  16. Yu. Yu. Orlov, V. M. Alifirova, N. V. Cherdyntseva, et al., “Results of a three-year clinical-immunological observations of patients with multiple sclerosis receiving Copaxone,” Zh. Nevrol. Psikhiat., 105, No. 5, 23–27 (2005).

    Google Scholar 

  17. T. E. Shmidt, I. G. Churkina, I. A. Elagina, and N. N. Yakhno, “The course of remitting multiple sclerosis on the background of treatment with Copaxone and after its withdrawal,” Nevrol. Zh., 10, No. 3, 23–28 (2005).

    Google Scholar 

  18. I. N. Abdurasulova, Yu. L. Zhitnukhin, E. A. Tarasova, and V. M. Klimenko, “Expression of cytokine mRNAs in the spleen and spinal cord in rats with EAE of different severities,” Med. Immunol., 6, No. 1–2, 37–46 (2004).

    Google Scholar 

  19. Yu. L. Zhitnukhin, I. N. Abdurasulova, E. A. Tarasova, et al., “Features of the dynamics of circulating and expressible cytokines in the induction of experimental allergic encephalomyelitis,” Med. Immunol., 10, No. 2–3, 193–202 (2008).

    Google Scholar 

  20. N. B. Serebryanaya, M. N. Karpenko, Yu. L. Zhitnukhin, and I. N. Abdurasulova, “Studies of the protective action of Ferrovir in acute experimental allergic encephalomyelitis,” Zh. Tsitok Vospal., 9, No. 1, 33–39 (2010).

    Google Scholar 

  21. M. D. Carruthers, “ Update on disease-modifying treatments for multiple sclerosis,” Clin. Ther., 36, No. 12, 1938–1945 (2014), doi: 10.1016/j.clinthera.2014.08.006.

    Article  Google Scholar 

  22. J. Steiner, N. Marquardt, I. Pauls, et al., “Human CD8+ T cells and NK cells express and secrete S100B upon stimulation,” Brain Behav. Immun., 25, 1233–1241 (2011), doi: 10.1016/j.bbi.2011.03.015.

    Article  CAS  PubMed  Google Scholar 

  23. T. Petrova, J. Hu, and L. J. Van Eldik, “Modulation of glial activation by astrocyte-derived protein S100B: differential responses of astrocyte and microglial cultures,” Brain Res., 853, 74–80 (2000), doi: 10.1016/s0006-8993(99)02251-9.

    Article  CAS  PubMed  Google Scholar 

  24. C. Adami, R. Bianchi, G. Pula, and R. Donato, “S100B-stimulated NO production by BV-2 microglia is independent of RAGE transducing activity but dependent on RAGE extracellular domain,” Biochim. Biophys. Acta, 1742, 169–177 (2004), doi: 10.1016/j.bbamcr.2004.09.008.

    Article  CAS  PubMed  Google Scholar 

  25. R. Donato, G. Sorci, F. Riuzzi, et al., “S100’s double life: intracellular regulator and extracellular signal,” Biochim. Biophys. Acta, 1793, 1008–1022 (2009), doi: 10.1016/j.bbamcr.2008.11.009.

    Article  CAS  PubMed  Google Scholar 

  26. C. Reali, R. Pillai, F. Saba, et al., “S100B modulates growth factors and costimulatory molecules expression in cultured human astrocytes,” J. Neuroimmunol., 243, 95–99 (2012), doi: 10.1016/j.jneuroim.2011.11.011.

    Article  CAS  PubMed  Google Scholar 

  27. D. S. Goncalves, G. Lenz, J. Karl, et al., “Extracellular S100B protein modulates ERK in astrocyte cultures,” Neuroreport, 11, No. 4, 807–809 (2000), doi: 10.1097/00001756-200003200-00030.

Download references

Author information

Authors and Affiliations

  1. Materia Medica Holding, Scientific and Production Company, Moscow, Russia

    K. K. Ganina, Yu. L. Dugina, K. S. Zhavbert, I. A. Ertuzun & O. I. Epshtein

  2. Institute of Experimental Medicine, Moscow, Russia

    I. N. Abdurasulova

Authors
  1. K. K. Ganina
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yu. L. Dugina
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. K. S. Zhavbert
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. I. A. Ertuzun
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. O. I. Epshtein
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. I. N. Abdurasulova
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to K. K. Ganina.

Additional information

Translated from Zhurnal Nevrologii i Psikhiatrii imeni S. S. Korsakova, Vol. 115, No. 6, Iss. 1, pp. 78–82, June, 2015.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ganina, K.K., Dugina, Y.L., Zhavbert, K.S. et al. Release-Active Antibodies to S100 Protein Can Correct the Course of Experimental Allergic Encephalomyelitis. Neurosci Behav Physi 47, 163–167 (2017). https://doi.org/10.1007/s11055-016-0380-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11055-016-0380-0

Keywords

Search

Navigation